在产前症中,孕产妇的三甲酸催化剂和胰岛素抵抗参数
Zainab Abdulameer Jasim1, Hussein Kadhem Al-Hakeim2, Samaneh Zolghadri3
1Department of Biochemistry, Shiraz Branch, Islamic Azad University, Shiraz 7198774731, Iran.
Biomolecules
|October 28, 2023
概括
孕前症涉及改变的托芬催化剂和胰岛素抵抗. 降低的托芬和升高的3-基氨,以及胰岛素耐药性,可以帮助预测孕妇的孕前.
科学领域:
- 生物化学 生化学
- 产科 产科 产科 产科 产科
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 孕前 (PE) 是严重的第三个月的妊娠并发症,以高血压和蛋白尿为特征.
- 早期发育涉及显著的代谢和生化变化,需要新的诊断和监测生物标志物.
- 目前对PE的诊断方法需要改进,强调需要新的预测标志物.
研究的目的:
- 为了研究酸盐催化剂 (TRYCATs) 和胰岛素抵抗 (IR) 参数在孕前的诊断效用.
- 评估TRYCATs,IR和临床因素在产前病理生理学中的关系.
- 评估特定的TRYCAT和红外线标记物用于预先怀孕检测的预测能力.
主要方法:
- 一项病例控制研究,涉及60名患有孕前的妇女和60名健康的孕妇对照.
- 测量了托芬,氨酸,氨酸,3-氧氨酸,胰岛素和葡萄糖的血清水平.
- 与酶相关的免疫吸收试验 (ELISA) 和光谱测量用于生物化学分析.
主要成果:
- 与对照人群相比,患有PE的女性的血清托芬水平显著降低.
- 在PE患者中观察到高水平的氨酸,氨酸/氨酸比率,氨酸/氨酸比率和3-氧氨酸.
- PE与胰岛素抵抗状态有关,在IR,TRYCAT和临床数据之间发现了显著的相关性.
结论:
- 孕前的病理生理学与胰岛素耐药性和托芬催化剂系统的失调有关.
- 特定的变化,包括降低托芬和增加3-基氨,以及IR,显示出预测PE的潜力.
- 这些代谢变化值得在临床诊断和孕前的治疗中加以考虑.
更多相关视频
12:17The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
Published on: August 2, 2017
10.7K
12:02Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
15.9K
相关概念视频
Pathophysiology of Diabetes
956
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
956
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Inborn Errors of Metabolism
167
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
167
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
